SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing significant volatility and trending downward after investors reacted negatively to conservative guidance and ongoing concerns about soft sales in China, despite the company posting a double earnings beat. The community is deeply divided, with many retail investors labeling the brand as 'stale' or 'woke' while others view the depressed price as a generational buying opportunity for a long-term turnaround.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF (NASA) is drawing significant attention as traders debate whether its small asset base and exposure to SpaceX represent a promising new momentum play or a potential risk. Community discussion is sharply divided, with some investors eyeing the ticker for its high-volatility potential and similarities to recent thematic ETF surges, while others express skepticism over its low assets under management and limited holdings.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community discussions as it faces significant price volatility and touches new lows, prompting intense debate between long-term "hodlers" maintaining conviction in its technology and skeptics questioning the project's viability. Market sentiment is heavily divided between those seeking bargain entry points based on institutional partnerships and those exiting due to concerns over management, staff reductions, and stagnant network activity compared to broader crypto sector performance.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is seeing intense community debate as investors weigh its status as a battle-tested DeFi protocol against significant price volatility and concerns over governance efficacy. While some holders point to a capped supply and potential for V4 protocol updates as a catalyst for a rebound, many participants are expressing frustration over persistent downward pressure and are actively comparing its performance to competitors like AAVE.

Ganymede

Ganymede is gaining traction as community members highlight its stable price structure and deliberate accumulation phase as indicators of potential upward momentum. Investors are actively discussing the token's steady progression and disciplined market behavior, viewing the current setup as an opportunity to build positions before further volatility.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation is capturing significant investor attention as stakeholders eagerly anticipate upcoming earnings and potential updates regarding the Yartemlea commercial launch. While the stock continues to face downward pressure from heavy short interest, the community remains intensely focused on the company's financial runway, the Novo Nordisk milestone payments, and the upcoming European regulatory path as key catalysts for a potential reversal.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom is currently at the center of intense debate among retail traders who are vocally frustrated by stagnant price action and perceived market manipulation, while technical analysts closely monitor critical support levels and potential gap-fill opportunities following the company's recent product developments. The community is actively debating whether the stock is an oversold buying opportunity poised for a technical bounce or a fundamental value trap facing continued institutional selling pressure.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is currently drawing significant attention from investors ahead of its earnings report, with the community polarized between those betting on long-term institutional growth through AI-driven insurance tech and those skeptical of its operational efficiency and membership retention. Conversations remain heavily focused on the company's ability to achieve profitability in 2026, the potential impact of ACA policy shifts, and whether the stock's recent price volatility represents a buying opportunity or a deeper structural decline.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is capturing significant investor attention ahead of its third-quarter earnings report, with community sentiment bolstered by the company's aggressive expansion into AI-powered surveillance tools and recent strategic investments in the crypto sector. Traders are closely monitoring the stock for potential volatility and breakout opportunities, frequently citing the integration of advanced technologies and long-term growth initiatives as key catalysts for their bullish outlook.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing heightened investor activity as the market reacts to broader biotech M&A trends and positive phase 3 enrollment updates for its obesity pipeline. The community remains focused on the company's potential as a buyout candidate, with long-term holders actively debating the company's competitive positioning against industry giants while navigating short-term market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology Rigel Announces Publication of Final ARROW...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendat...

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Lowered to "Hold" at Wall Street Zen

Wall Street Zen cut Rigel Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday...

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Down - What's Next?

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Down - Time to Sell...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have been assigned a consensus rating of "Hold" from the seven research firms that are covering the company, Marketbeat Ratings...

Rigel Pharmaceuticals Q4 Earnings Call Highlights

Rigel Pharmaceuticals (NASDAQ:RIGL) detailed record commercial performance for the fourth quarter and full year 2025, while outlining plans to pursue additional in-licensing opportunities and advance...

Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Summary: Rigel Pharmaceuticals Q4

Rigel Pharmaceuticals (NASDAQ:RIGL) Announces Earnings Results

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) issued its quarterly earnings data on Tuesday. The biotechnology company reported $13.54 earnings per share (EPS) for the quarter, beating...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

RIGL
Rigel Pharmaceuticals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RIGL News

RIGLRigel Pharmaceuticals